Jan Skvarka
Director/Board Member at ZENTALIS PHARMACEUTICALS, INC.
Net worth: 764 030 $ as of 31/03/2024
Profile
Jan Skvarka is currently the Executive Chairman at GentiBio, Inc. and DEM BioPharma, Inc. He is also an Independent Director at Zentalis Pharmaceuticals, Inc. and Monte Rosa Therapeutics, Inc. Dr. Skvarka was previously the President, Chief Executive Officer & Director at Trillium Therapeutics ULC and Tal Medical, Inc. He was also a Partner-Healthcare Practice at Bain & Co., Inc. and a Manager at PricewaterhouseCoopers LLP (United Kingdom).
Dr. Skvarka holds a doctorate from the University of Bratislava Economic and an MBA from Harvard Business School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
11/09/2023 | 47,970 ( 0.07% ) | 756 007 $ | 31/03/2024 | |
31/03/2023 | 1,138 ( 0.00% ) | 8 023 $ | 31/03/2024 |
Jan Skvarka active positions
Companies | Position | Start |
---|---|---|
ZENTALIS PHARMACEUTICALS, INC. | Director/Board Member | 12/09/2022 |
MONTE ROSA THERAPEUTICS, INC. | Director/Board Member | 23/03/2023 |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Chairman | - |
DEM BioPharma, Inc.
DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | Chairman | - |
Former positions of Jan Skvarka
Companies | Position | End |
---|---|---|
TRILLIUM THERAPEUTICS | Chief Executive Officer | 17/11/2021 |
Bain & Co., Inc.
Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
PricewaterhouseCoopers LLP (United Kingdom)
PricewaterhouseCoopers LLP (United Kingdom) Other Consumer ServicesConsumer Services PricewaterhouseCoopers LLP engages in the provision of accounting services. Its services include audit and assurance, accounting advisory, risk assurance, tax management, corporate insolvency, life cycle assessment, forensic services, private equity advisory, and financial reporting valuations. The company is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Tal Medical, Inc.
Tal Medical, Inc. Medical SpecialtiesHealth Technology Tal Medical, Inc. operates as a clinical stage medical device company. It develops novel, non contact, neuromodulatory devices for the treatment of psychiatric and neurological disorders. The firm focuses on the development of LFMS for the treatment of major depressive disorder and bipolar depression. The company was founded by Daphne Zohar, Steven Marc Paul, Andrew Miller, Eric Elenko and Nessan Bermingham in 2010 and is headquartered in Boston, MA. | Chief Executive Officer | - |
Training of Jan Skvarka
University of Bratislava Economic | Doctorate Degree |
Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
Private companies | 7 |
---|---|
Trillium Therapeutics ULC
Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Tal Medical, Inc.
Tal Medical, Inc. Medical SpecialtiesHealth Technology Tal Medical, Inc. operates as a clinical stage medical device company. It develops novel, non contact, neuromodulatory devices for the treatment of psychiatric and neurological disorders. The firm focuses on the development of LFMS for the treatment of major depressive disorder and bipolar depression. The company was founded by Daphne Zohar, Steven Marc Paul, Andrew Miller, Eric Elenko and Nessan Bermingham in 2010 and is headquartered in Boston, MA. | Health Technology |
Bain & Co., Inc.
Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA. | Commercial Services |
PricewaterhouseCoopers LLP (United Kingdom)
PricewaterhouseCoopers LLP (United Kingdom) Other Consumer ServicesConsumer Services PricewaterhouseCoopers LLP engages in the provision of accounting services. Its services include audit and assurance, accounting advisory, risk assurance, tax management, corporate insolvency, life cycle assessment, forensic services, private equity advisory, and financial reporting valuations. The company is headquartered in London, the United Kingdom. | Consumer Services |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Health Technology |
Monte Rosa Therapeutics, Inc. | |
DEM BioPharma, Inc.
DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | Health Technology |
- Stock Market
- Insiders
- Jan Skvarka